NASDAQ:AUGX Augmedix (AUGX) Stock Price, News & Analysis → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free AUGX Stock Alerts $1.23 +0.04 (+3.36%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.2350-Day Range$1.15▼$4.2552-Week Range$0.99▼$6.25Volume1.68 million shsAverage Volume556,010 shsMarket Capitalization$60.23 millionP/E RatioN/ADividend YieldN/APrice Target$3.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Augmedix alerts: Email Address Augmedix MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside215.0% Upside$3.88 Price TargetShort InterestBearish3.84% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 24 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.78 out of 5 starsMedical Sector675th out of 921 stocksBusiness Services, Not Elsewhere Classified Industry78th out of 90 stocks 3.3 Analyst's Opinion Consensus RatingAugmedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAugmedix has only been the subject of 4 research reports in the past 90 days.Read more about Augmedix's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.84% of the float of Augmedix has been sold short.Short Interest Ratio / Days to CoverAugmedix has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Augmedix has recently increased by 36.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAugmedix does not currently pay a dividend.Dividend GrowthAugmedix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUGX. Previous Next 1.8 News and Social Media Coverage News SentimentAugmedix has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Augmedix this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for AUGX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Augmedix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Augmedix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,005,527.00 in company stock.Percentage Held by Insiders10.97% of the stock of Augmedix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.11% of the stock of Augmedix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Augmedix's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Augmedix is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Augmedix is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAugmedix has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Augmedix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Augmedix Stock (NASDAQ:AUGX)Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.Read More AUGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUGX Stock News HeadlinesMay 17 at 2:34 AM | americanbankingnews.comB. Riley Analysts Boost Earnings Estimates for Augmedix, Inc. (NASDAQ:AUGX)May 15 at 8:45 AM | benzinga.comLatest News for Augmedix Stock (NASDAQ:AUGX)May 15 at 6:21 AM | americanbankingnews.comAugmedix (NASDAQ:AUGX) Downgraded by Maxim Group to "Hold"May 15 at 6:21 AM | americanbankingnews.comAugmedix (NASDAQ:AUGX) Stock Rating Lowered by Evercore ISIMay 15 at 5:36 AM | americanbankingnews.comAugmedix (NASDAQ:AUGX) PT Lowered to $3.50May 14 at 10:08 AM | finanznachrichten.deAugmedix Inc: Augmedix Delivers 40% Revenue Growth for First Quarter of 2024May 14 at 10:08 AM | msn.comAugmedix, Inc. (NASDAQ:AUGX) Q1 2024 Earnings Call TranscriptMay 14 at 8:34 AM | investorplace.comWhy Is Augmedix (AUGX) Stock Down 41% Today?May 14 at 5:07 AM | finance.yahoo.comAugmedix Inc (AUGX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ChallengesMay 13, 2024 | globenewswire.comAugmedix Delivers 40% Revenue Growth for First Quarter of 2024May 11, 2024 | americanbankingnews.comAugmedix (AUGX) Scheduled to Post Earnings on MondayMay 3, 2024 | globenewswire.comAugmedix to Participate in Upcoming Investor Conferences in May and June 2024April 30, 2024 | finance.yahoo.comAugmedix to Announce First Quarter 2024 Financial Results on May 13, 2024April 27, 2024 | stockhouse.comAugmedix Awarded on Newsweek's World's Best Digital Health Companies 2024 ListApril 24, 2024 | finance.yahoo.comAugmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsApril 24, 2024 | globenewswire.comAugmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency DepartmentsApril 19, 2024 | investorplace.com3 Penny Stocks That Could Make a Big Comeback by the End of Q2April 17, 2024 | msn.comAugmedix (AUGX) Price Target Decreased by 6.38% to 6.19April 14, 2024 | investing.comAugmedix's chief strategy officer sells shares worth over $369kApril 12, 2024 | finance.yahoo.comInsider Sell: Augmedix Inc's (AUGX) Chief Strategy Officer Ian Shakil Sells 92,787 SharesApril 11, 2024 | investing.comAugmedix shares upgraded to Outperform by Evercore ISIApril 9, 2024 | markets.businessinsider.comAnalyst Ratings For AugmedixApril 9, 2024 | globenewswire.comAugmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual CareApril 5, 2024 | finance.yahoo.comAugmedix Inc (AUGX) Chief Strategy Officer Ian Shakil Sells 109,961 SharesApril 4, 2024 | globenewswire.comAugmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems NationwideSee More Headlines Receive AUGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/16/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:AUGX CUSIPN/A CIK1769804 Webwww.augmedix.com Phone888-669-4885FaxN/AEmployees1,430Year FoundedN/APrice Target and Rating Average Stock Price Target$3.88 High Stock Price Target$5.50 Low Stock Price Target$1.50 Potential Upside/Downside+215.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,170,000.00 Net Margins-41.95% Pretax Margin-42.42% Return on Equity-218.55% Return on Assets-40.48% Debt Debt-to-Equity Ratio0.66 Current Ratio2.41 Quick Ratio2.41 Sales & Book Value Annual Sales$44.85 million Price / Sales1.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book2.20Miscellaneous Outstanding Shares48,970,000Free Float43,596,000Market Cap$60.23 million OptionableOptionable Beta0.03 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Emmanuel Krakaris (Age 65)President, CEO, Secretary & Director Comp: $734.33kMr. Ian Shakil (Age 39)Founder, Chief Strategy Officer & Director Ms. Sandra Breber (Age 66)Chief Operating Officer Comp: $446.05kMr. Saurav Chatterjee Ph.D. (Age 52)Chief Technology Officer Comp: $438.05kMr. Paul Louis Ginocchio (Age 54)Chief Financial Officer Todd HolvickHead of Legal & ComplianceLia WallickHead of PeopleDr. Davin Lundquist M.D.Chief Medical OfficerMr. Jonathan Hawkins (Age 54)Chief Revenue Officer Comp: $417.71kMr. Tomer LevySenior Vice President of EngineeringMore ExecutivesKey CompetitorsNutex HealthNASDAQ:NUTXAmerican WellNYSE:AMWLGenenta ScienceNASDAQ:GNTACheckpoint TherapeuticsNASDAQ:CKPTCarisma TherapeuticsNASDAQ:CARMView All CompetitorsInsiders & InstitutionsAncora Advisors LLCBought 225,330 shares on 5/16/2024Ownership: 0.908%Kennedy Capital Management LLCSold 28,564 shares on 5/16/2024Ownership: 0.757%FourWorld Capital Management LLCBought 50,515 shares on 5/16/2024Ownership: 0.103%Hood River Capital Management LLCBought 216,339 shares on 5/15/2024Ownership: 1.001%PEAK6 Investments LLCBought 27,478 shares on 5/15/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions AUGX Stock Analysis - Frequently Asked Questions Should I buy or sell Augmedix stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUGX shares. View AUGX analyst ratings or view top-rated stocks. What is Augmedix's stock price target for 2024? 3 equities research analysts have issued 1-year price objectives for Augmedix's shares. Their AUGX share price targets range from $1.50 to $5.50. On average, they anticipate the company's stock price to reach $3.88 in the next twelve months. This suggests a possible upside of 215.0% from the stock's current price. View analysts price targets for AUGX or view top-rated stocks among Wall Street analysts. How have AUGX shares performed in 2024? Augmedix's stock was trading at $5.85 at the start of the year. Since then, AUGX shares have decreased by 79.0% and is now trading at $1.23. View the best growth stocks for 2024 here. When is Augmedix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our AUGX earnings forecast. How were Augmedix's earnings last quarter? Augmedix, Inc. (NASDAQ:AUGX) posted its earnings results on Monday, March, 18th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $12.68 million for the quarter, compared to analysts' expectations of $12.30 million. Augmedix had a negative net margin of 41.95% and a negative trailing twelve-month return on equity of 218.55%. What guidance has Augmedix issued on next quarter's earnings? Augmedix issued an update on its FY 2024 earnings guidance on Monday, May, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.0 million-$55.0 million, compared to the consensus revenue estimate of $61.2 million. When did Augmedix IPO? Augmedix (AUGX) raised $40 million in an initial public offering (IPO) on Tuesday, October 26th 2021. The company issued 10,000,000 shares at $4.00 per share. William Blair, B. Riley Securities, Benchmark and Lake Street served as the underwriters for the IPO. Who are Augmedix's major shareholders? Augmedix's stock is owned by a number of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (2.98%), Vanguard Group Inc. (2.66%), Russell Investments Group Ltd. (1.34%), Essex Investment Management Co. LLC (1.08%), Hood River Capital Management LLC (1.00%) and Ancora Advisors LLC (0.91%). Insiders that own company stock include Ian Shakil and Paul Ginocchio. View institutional ownership trends. How do I buy shares of Augmedix? Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUGX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Augmedix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
